Core Viewpoint - The recent advancements in innovative drug development by Yuan Da Pharmaceutical have significantly boosted its stock price, reflecting the growing importance of innovative drugs in the market [1][4]. Group 1: Company Developments - Yuan Da Pharmaceutical announced the completion of patient enrollment for its innovative radiopharmaceutical TLX591-CDx, with plans to submit a new drug application in China this year [1][2]. - The company is one of only four globally to commercialize innovative nuclear drugs, with TLX591-CDx targeting metastatic and recurrent prostate cancer [2]. - The drug has shown promising results in a Phase III clinical study involving over 100 patients, assessing its diagnostic efficacy and safety in the Chinese population [2][3]. - Yuan Da has a robust pipeline with 15 innovative products in the development phase, focusing on various cancers, including liver, prostate, kidney, and brain cancers [3]. Group 2: Market Performance - Following the announcements, Yuan Da's stock price surged to a historical high of 8.95 HKD per share, marking a cumulative increase of 38.4% from May 7 to May 13 [1][4]. - The overall pharmaceutical sector, particularly innovative drugs, is experiencing a resurgence, with the Hong Kong innovative drug index showing a cumulative increase of 22.67% this year [4]. - The company's core product, Yttrium-90 microsphere injection, has become a key revenue driver, contributing nearly 500 million HKD in revenue for 2024, with a year-on-year growth rate exceeding 140% [3].
远大医药连发创新药进展引资本关注，5个交易日股价涨幅超38%